Reproductive Medicine
Shahrzad Zademodares; Masoumeh Abbaspour; Maryam Anbarluei; Nayereh Rahmati; Marzieh Fathi; Zahra Naeiji
Volume 6, Issue 4 , August 2021, , Pages 161-166
Abstract
Background & Objective: This retrospective study aims to evaluate the impact of pre-gestational maternal age and body weight on the outcome of IVF in women with polycystic ovary syndrome (PCOS). Materials & Methods: Medical records of 200 known cases of PCOS treated in a third level ...
Read More
Background & Objective: This retrospective study aims to evaluate the impact of pre-gestational maternal age and body weight on the outcome of IVF in women with polycystic ovary syndrome (PCOS). Materials & Methods: Medical records of 200 known cases of PCOS treated in a third level referral center by the same therapeutic protocol were evaluated retrospectively. Demographic data, maternal body mass index (BMI), hormonal profile (LH, FSH, estradiol, and anti-mullerian), IVF cycle parameters and outcomes were documented. Patients were categorized into three groups based on their BMI (normal=18.5-24.9, overweight=25-30, obese≥30). IVF cycle parameters and outcomes were compared in the three groups. Effect of age was also evaluated by comparing the results in patients aged <35 and ≥35.Results: Mean age of patients was 32.5 (±5.2). A number of 72 patients had normal BMI, 85 patients were overweighed and 43 cases were obese. Baseline hormonal profile was similar in the three groups. Total dose of administered FSH was similar in the three groups. Number of retrieved oocytes was significantly higher in patients with BMI>30 but the number of mature oocytes and number of embryos were statistically lower in this group. Size of follicles showed no statistically significant difference in the three groups. Clinical pregnancy rate was significantly lower in patients with BMI>30 kg/m2 and age>35 years old.Conclusion: BMI>30 and age>35 years old have a statistically significant negative impact on IVF success rate.
Mina Jafarabadi; Fatemeh Ramezanzadeh; Samarand Salimi; Tahereh Forooghifar
Volume 2, Issue 1 , March and April 2017
Abstract
Background: Both in-vitro maturation and in-vitro fertilization have been used successfully to treat females with polycystic ovarian syndrome, who plan to have child. This study compared outcome of these two approaches to fertilize females with polycystic ovary side effects.
Methods: This prospective ...
Read More
Background: Both in-vitro maturation and in-vitro fertilization have been used successfully to treat females with polycystic ovarian syndrome, who plan to have child. This study compared outcome of these two approaches to fertilize females with polycystic ovary side effects.
Methods: This prospective study was conducted at Vali-Asr reproductive health research center and included all females with polycystic ovarian syndrome, who underwent in-vitro maturation or in-vitro fertilization from January 2005 to January 2008. Measurements included demographic data, total cost (including drug and laboratory procedures), outcome (chemical and clinical pregnancy), and systemic complication (ovarian hyper-stimulation syndrome), obtained from the patients’ clinical files. Patients were informed about the procedures, side effects and goals, and the signed consent form for surgical approaches and use of their data in medical research. Finally, these variables were compared between the two groups.
Results: The in-vitro maturation and in-vitro fertilization groups included 20 and 22 patients, respectively. The range of body mass index was between 17.4 and 28.3 kg/m2 and the mean age of the patients was 29.35 ± 4.94 and 28.95 ± 3.84 years, respectively (P > 0.05). The total cost was significantly lower in in-vitro maturation group compared to in-vitro fertilization (201.6 ± 60.1 USD versus 380.5 ± 143.8 USD, respectively, P < 0.001). Positive outcomes were achieved significantly more frequently with the in-vitro fertilization method (1 chemical and no clinical pregnancy in in-vitro maturation versus 7 and 6 in in-vitro fertilization group, respectively, P < 0.001). Although, the rate of ovarian hyper-stimulation syndrome was higher in in-vitro fertilization than in in-vitro maturation approach, yet, it was not statistically significant (P = 0.233).
Conclusions: Our findings showed the superiority of execution of the in-vitro fertilization approach compared with the in-vitro maturation method in infertile females with polycystic ovary syndrome, who planned to have a child. However, in-vitro maturation approach is cheaper than in-vitro fertilization and is also associated with lower risk of ovarian hyper-stimulation syndrome.
